Sublingual immunotherapy (SLIT) vs. Subcutaneous immunotherapy (SCIT) Canonica G.W. Personalized Medicine Clinic Asthma & Allergy.
|
|
|
- Prosper Murphy
- 5 years ago
- Views:
Transcription
1 Sublingual immunotherapy (SLIT) vs. Subcutaneous immunotherapy (SCIT) Canonica G.W. Personalized Medicine Clinic Asthma & Allergy Milano Italy President President
2 G.Walter CANONICA DISCLOSURE OF INTERESTS Prof. Giorgio Walter CANONICA, in the last five years,has been: -scientific consultant as a single scientist or in national/international boards, -researcher in scientific trials in his university or in collaboration with other research institutions, -speaker in scientific meetings,seminars and educational activities devoted to specialists, general practitioners and other healthcare professionals, totally or partially supported by the following commercial companies: - A.Menarini - Alk-Abello - Almirall - Allergy Therapeutics - Anallergo - AstraZeneca - Boeringher Ingelheim - Boston Scientific - Bruschettini - Chiesi Farmaceutici - Circassia - Danone - Faes - Glaxo Smith Kline - Lab.Guidotti - Lallemand - Lofarma - Malesci - Meda Pharma - Mundifarma - Novartis - Pfizer - Roche - Sanofi - Stallergenes - Thermo Fisher - Uriach - Teva - Valeas
3 Canonica et al. Curr..Opin.Pulm.Med. 2015
4 Canonica et al. Curr..Opin.Pulm.Med. 2015
5 Passalacqua & Canonica Imm Allergy Clin North Am 2015
6 Passalacqua & Canonica, Imm Allergy Clin North Am 2015
7 The PREMISE
8 de Bot et al PAI 2011
9 de Bot et al PAI 2011
10 2012 Letter to the Editor by Bachert C., Canonica G.W., Bufe A.
11 2012 Bachert C., Canonica G.W., Bufe A., PAI 2012
12 Bachert C., Canonica G.W., Bufe A., PAI We therefore suggest to specify the SIT product in the title of the publication, and to avoid unjustified general statements on application routes or patient groups. Yours faithfully, Claus Bachert, G. Walter Canonica, Albrecht Bufe
13 Bachert et al. WAO J 2015
14 Bachert et al. WAO J 2015
15 Bachert et al. WAO J 2015
16 Bachert et al. WAO J 2015
17 The AIM is to declare: PRODUCT X...due to its features, meets the international requirements
18
19 Canonica et al. Curr..Opin.Pulm.Med. 2015
20 Dretzke et al JACI 2013
21 Dretzke et al JACI 2013
22 Narkus et al. CTA 2013
23 Narkus et al. CTA 2013
24 Placebo effect Narkus et al. CTA 2013
25 Narkus et al. CTA 2013
26 AIT ADHERENCE
27
28
29 Leader et al.,int.f.allergy & Rhinology 2015
30 Leader et al.,int.f.allergy & Rhinology 2015
31 Conclusion Leader et al.,int.f.allergy & Rhinology 2015
32 Nachson et al., ACAAI 2015
33 @health can improve adherence Nachson et al., ACAAI 2015
34 Eifen et al C.E.I. 2011
35 Eifen et al C.E.I. 2011
36 Eifen et al C.E.I. 2011
37 Primary Outcome VAS Eifen et al C.E.I. 2011
38 NPT IgE SPT Eifen et al C.E.I. 2011
39 IL-10 TGFb Eifen et al C.E.I. 2011
40 Eifen et al C.E.I. 2011
41 Keles et al JACI 2011
42 Dose of ICS # asthma attacks/year Keles et al JACI 2011
43 Der p1 induced IL 10 Der p1 induced TGFb Der f1 induced IL 10 Der f1 induced TGFb Keles et al JACI 2011
44 Keles et al JACI 2011
45 PubMed October
46 Tabataian & Casale All Asthma Proc 2016
47 Tabataian & Casale All Asthma Proc 2016
48
49 KEY MESSAGE
50 Durham & Penagos JACI 2016
51 SAR Durham & Penagos JACI 2016
52 Durham & Penagos JACI 2016
53 KEY POINTS Durham & Penagos JACI 2016
54 Durham & Penagos JACI 2016
55 Key Messages Durham & Penagos JACI 2016
56 AIT HEALTH CARE COSTs
57 Verheggen et al. Clin Trans.Allergy 2015
58 Verheggen et al. Clin Trans.Allergy 2015
59 Verheggen et al. Clin Trans.Allergy 2015
60 Verheggen et al. Clin Trans.Allergy 2015
61 Linda Cox 2015
62 Linda Cox 2015
63 Linda Cox 2015
64 Linda Cox 2015
65 Canonica et al. Curr..Opin.Pulm.Med. 2015
66 Bachert et al. WAO J 2015
67 Ronborg et al.j.m.e. 2016
68 Ronborg et al.j.m.e. 2016
69 Conclusion With regards to the cost of treating Danish patients with HDM RAD, it is to treat patients with. Ronborg et al., J.M.E. 2016
70 AIT CURRENT REAL LIFE FACTS 1
71 McDonell et al. All.Asthma Clin.Immunol 2015
72 SCIT SLIT drops slit tablets McDonell et al. All.Asthma Clin.Immunol 2015
73 McDonell et al. All.Asthma Clin.Immunol 2015
74 McDonell et al. All.Asthma Clin.Immunol 2015
75 McDonell et al. All.Asthma Clin.Immunol 2015
76 AIT CURRENT REAL LIFE FACTS 2
77 PATIENTS in Randomized Controlled Trials & in everyday Clinical Practice Patients selected in RCTs Patients in everyday Clinical Practice
78 Roche et al Annals ATS 2013
79 Saporta D., J.E.P.H. 2012
80 PURPOSE Saporta D., J.E.P.H. 2012
81 CLINICAL PRACTICE DATA Saporta D., J.E.P.H. 2012
82 SLIT or SCIT Saporta D., J.E.P.H. 2012
83 TEST PANEL Saporta D., J.E.P.H. 2012
84 Saporta D., J.E.P.H. 2012
85 Saporta D., J.E.P.H. 2012
86 Saporta D., J.E.P.H. 2012
87 Saporta D., J.E.P.H. 2012
88 Very Final Message
89 Canonica et al. Curr..Opin.Pulm.Med. 2015
90
Secondary prevention of allergic disease. Dr Adam Fox United Kingdom
Secondary prevention of allergic disease Dr Adam Fox United Kingdom Disclosures Lecture fees: Danone, Mead Johnson, ALK-Abello, Stallergenes, Allergy Therapeutics Industry-sponsored grant: Danone, ALK-Abello
Speaking the Same Language: Grading System for Subcutaneous Immunotherapy Systemic Reaction World Allergy Organization Symposium Immunotherapy &
Speaking the Same Language: Grading System for Subcutaneous Immunotherapy Systemic Reaction World Allergy Organization Symposium Immunotherapy & Biologics 2012 Chicago Linda Cox, MD, FAAAAI Linda Cox,
Use of SLIT in allergy practice: Is it ready for prime time? Stanley Fineman, MD, MBA Atlanta Allergy & Asthma Clinic AAIFNC, Feb 7, 2015
Use of SLIT in allergy practice: Is it ready for prime time? Stanley Fineman, MD, MBA Atlanta Allergy & Asthma Clinic AAIFNC, Feb 7, 2015 Disclosures Speakers bureau/consultant: AZ, Genentech/Novartis,
Asthma is a major public health problem that affects an
ORIGINAL ARTICLE Barriers to Asthma Treatment in the United States: Results From the Global Asthma Physician and Patient Survey Michael S. Blaiss, MD, 1 Michael A. Kaliner, MD, 2 Carlos E. Baena-Cagnani,
Introduction. Methods. Results 12/7/2012. Immunotherapy in the Pediatric Population
12/7/212 Introduction Immunotherapy in the Pediatric Population Michael S. Blaiss, MD Clinical Professor of Pediatrics and Medicine University of Tennessee Health Science Center Memphis, Tennessee Allergen
Nonlife-threatening systemic adverse events account for a minority of SLIT-related side effects. According to the World Allergy
Safety and Tolerability of Sublingual Immunotherapy in Clinical Trials and Real Life Gianenrico Senna, Marco Caminati, Giorgio Walter Canonica Curr Opin Allergy Clin Immunol. 2013;13(6):656-662. www.medscape.com
Minireview. Claus Bachert. Jakob Noergaard Andreasen b
Minireview Published online: January 30, 2016 Cost-Effectiveness of Immunotherapy in the Treatment of Seasonal Allergic Rhinitis: Identifying Product-Specific Parameters of Relevance for Health Care Decision-Makers
Allergen Immunotherapy: An Update
Allergen Immunotherapy: An Update Susan Waserman MSc MDCM FRCPC Professor of Medicine Division of Clinical Allergy and Immunology CTS Calgary April 26, 2014 Presenter Disclosure Presenter: Dr Susan Waserman
POSITION PAPER. Accepted for publication 2 February DOI: /all Edited by: Thomas Bieber
POSITION PAPER Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper O. Pfaar 1, P. Demoly 2,3, R.
We improve quality of life by preventing and curing allergy
We improve quality of life by preventing and curing allergy SEB Enskilda Nordic Small & Mid Cap Seminar 2008 Jens Bager, President & CEO ALK-Abelló a fast growing pharmaceutical company Global pharmaceutical
Which Factors Might Enhance Safety of Immunotherapy in Your Clinic?
Which Factors Might Enhance Safety of Immunotherapy in Your Clinic? David I. Bernstein MD FAAAI Professor of Medicine and Environmental Health Division of Immunology and Allergy University of Cincinnati
SLIT: Review and Update
SLIT: Review and Update Disclosure Speaker: ISTA Pharmaceuticals Speaker: GlaxoSmithKline Allergen IT - Evidence Based Evaluation: Rescue Medications Meta-analysis Disease IT # of Patients Rescue Medication
ALK-Abelló A/S. Click View,Header and Footer to change this text to filename and department name
ALK-Abelló A/S June 25, 2008 Click View,Header and Footer to change this text to filename and department name 1 Changing the way we treat allergy Piper Jaffray 19th Annual Health Care Conference, New York
Assessing the Relative Risks of Subcutaneous and Sublingual Allergen Immunotherapy
Assessing the Relative Risks of Subcutaneous and Sublingual Allergen Immunotherapy Tolly Epstein, MD, MS Assistant Professor of Clinical Medicine Division of Immunology, Allergy & Rheumatology University
RECOMMENDATIONS FOR APPROPRIATE SLIT TRIALS
RECOMMENDATIONS FOR APPROPRIATE SLIT TRIALS Giovanni Passalacqua Allergy & Respiratory Diseases Dept.Internal MedicineIRCCS S.Martino IST University of Genoa ITALY CHICAGO-WAO-2013 ISHIZAKA NOON UK CSM
Allergen Immunotherapy in Asthma: Now and in the Future
Allergen Immunotherapy in Asthma: Now and in the Future Young-Il Koh, M.D. Chonnam National University Medical School, Gwangju, Korea 2017-03-25 CHONNAM NATIONAL UNIVERSITY MEDICAL SCHOOL 1 Management
Preventive effect of AIT over the atopic march
Preventive effect of AIT over the atopic march Susanne Halken, Professor, Pediatric Allergist Hans Christian Andersen Children s Hospital Odense University Hospital, DK Type Disclosure In relation to this
Expert Roundtable on Sublingual Immunotherapy
Expert Roundtable on Sublingual Immunotherapy FACULTY Linda Cox, MD Clinical Associate Professor, Nova Southeastern University Thomas Casale, MD Professor of Medicine, University of South Florida Peter
ALK-Abelló Research & Development. Henrik Jacobi MD, EVP Research & Development
ALK-Abelló Research & Development Henrik Jacobi MD, EVP Research & Development Agenda Latest news on GRAZAX 3rd year data from long-term study (GT-08) Effect on asthma symptoms in children (GT-12) Status:
Allergen Immunotherapy and Asthma. Linda Cox, MD, FAAAI ASCIA 2013 Meeting
Allergen Immunotherapy and Asthma Linda Cox, MD, FAAAI ASCIA 2013 Meeting Allergen Immunotherapy and Asthma Overview: burden/prevalence of asthma and allergic disease Allergen immunotherapy and asthma:
A world leader in allergy immunotherapy. Jefferies Global Healthcare Conference, London : 19 November 2014 : Flemming Pedersen, CFO & EVP
A world leader in allergy immunotherapy ALK at a glance Leading allergy immunotherapy (AIT) specialist AIT: Treats the root cause of allergy Products in all areas of AIT ALK has 33% of the global AIT market
Definition of Allergens 2013 Is there a need for Seasonal & Perennial?
MANIFESTO Definition of Allergens 2013 Is there a need for Seasonal & Perennial? Canonica G.W. Baena Cagnani C.E. Bousquet J. Pawankar R. Zuberbier T. Reasons for NOT using the classification of SEASONAL
A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress
DOI 10.1186/s13601-015-0080-9 RESEARCH Open Access A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress Peter W. Hellings 1,2*, Antonella Muraro
The Value of Real World evidence
The Value of Real World evidence Professor Ludger Klimek Center for Rhinology and Allergology Wiesbaden, Germany Disclosure Clinical studies: ALK-Abello, Danmark, Allergopharma, Germany, Artu-Biologicals,
Practical Course Allergen Immunotherapy (AIT) How to be effective. Michel Dracoulakis HSPE- FMO São Paulo-SP Brazil
Practical Course Allergen Immunotherapy (AIT) How to be effective Michel Dracoulakis HSPE- FMO São Paulo-SP Brazil Allergen immunotherapy - beginning Dunbar almost died with first inoculation 1911 Noon
Pediatric sublingual immunotherapy efficacy: evidence analysis,
Ann Allergy Asthma Immunol 110 (2013) 402e415 Contents lists available at SciVerse ScienceDirect Review Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009-2012 Désirée Larenas-Linnemann,
House Dust Mite Respiratory Allergy: An Overview of Current Therapeutic Strategies
Clinical Management Review House Dust Mite Respiratory Allergy: An Overview of Current Therapeutic Strategies Moisés A. Calderón, MD, PhD a,jörg Kleine-Tebbe, MD b, Allan Linneberg, MD, PhD c,d,e,frédéric
A world leader in allergy immunotherapy
A world leader in allergy immunotherapy R&D and Business Briefing New York, May 2014 ALK s equity story An emerging speciality pharma with a global growth strategy Jens Bager President and CEO Today s
HEALTH ECONOMIC ANALYSIS OF ALLERGEN IMMUNOTHERAPY (AIT) FOR THE MANAGEMENT OF ALLERGIC RHINITIS, ASTHMA, FOOD ALLERGY AND VENOM ALLERGY
7 HEALTH ECONOMIC ANALYSIS OF ALLERGEN IMMUNOTHERAPY (AIT) FOR THE MANAGEMENT OF ALLERGIC RHINITIS, ASTHMA, FOOD ALLERGY AND VENOM ALLERGY A SYSTEMATIC OVERVIEW Supplementary materials Miqdad Asaria 1,
journal Current status of sublingual immunotherapy in the United States Shelby Elenburg and Michael S Blaiss *
Elenburg and Blaiss World Allergy Organization Journal 2014, 7:24 journal REVIEW Open Access Current status of sublingual immunotherapy in the United States Shelby Elenburg and Michael S Blaiss * Abstract
Presentation of ALK London, 24 May 2011 UBS GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE : LONDON : 24 MAY 2011
Presentation of ALK London, 24 May 2011 1 ALK pharma specialist - treatment, prevention and diagnosis of allergies World leader in allergy immunotherapy ~ 33% global market share Expanding Base Business
Abstract and Introduction.
Sublingual Immunotherapy in Children: The Recent Experiences Nicole Pleskovic, Ashton Bartholow, David P. Skoner Curr Opin Allergy Clin Immunol. 2014;14(6):582-590. www.medscape.com Abstract and Introduction
Can dog allergen immunotherapy reduce concomitant allergic sensitization to other furry animals? A preliminary experience
L E T T ER T O T H E E D I T O R Eur Ann Allergy Clin Immunol Vol 49, N 2, 92-96, 2017 G. Liccardi 1,2, L. Calzetta 2,3, A. Salzillo 1, L. Billeri 4, G. Lucà 3, P. Rogliani 2,3 Can dog allergen immunotherapy
The Current Status of Sublingual Immunotherapy
The Current Status of Sublingual Immunotherapy Harold S. Nelson, MD Professor of Medicine National Jewish Health and University of Colorado Denver School of Medicine Denver, Colorado Disclosure: Harold
journal Recommendations for appropriate sublingual immunotherapy clinical trials Giovanni Passalacqua
Passalacqua World Allergy Organization Journal 2014, 7:21 journal REVIEW Recommendations for appropriate sublingual immunotherapy clinical trials Giovanni Passalacqua Open Access Abstract Sublingual immunotherapy
WORDS S UMMARY. R. Mösges, B. Ritter, G. Kayoko, D. Passali, S. Allekotte
Review Carbamylated monomeric allergoids... Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite and grass pollen induced allergic rhinoconjunctivitis: a
Sublingual immunotherapy for Alternaria-induced allergic rhinitis: a randomized placebo-controlled trial
Sublingual immunotherapy for Alternaria-induced allergic rhinitis: a randomized placebo-controlled trial Gabriele Cortellini, MD*; Igino Spadolini, MD ; Vincenzo Patella, MD ; Elisabetta Fabbri, BS ; Annalisa
Sublingual Immunotherapy as a Technique of Allergen Specific Therapy
Medical Policy Manual Medicine, Policy No. 121 Sublingual Immunotherapy as a Technique of Allergen Specific Therapy Next Review: October 2018 Last Review: October 2017 Effective: December 1, 2017 IMPORTANT
ACCURATE DIAGNOSIS OF ALLERGIC AIRWAY DISEASES
DEPARTMENT OF OTORHINOLARYNGOLOGY UPPER AIRWAYS RESEARCH LABORATORY ACCURATE DIAGNOSIS OF ALLERGIC AIRWAY DISEASES Prof Dr Philippe GEVAERT DISCLOSURES Phillipe Gevaert, MD, PhD, has disclosed the following
Abstract. Specific Immunotherapy (L Cox, Section Editor)
Curr Treat Options Allergy (2018) 5:275 290 DOI 10.1007/s40521-018-0176-2 Specific Immunotherapy (L Cox, Section Editor) Duration of Allergen Immunotherapy for Long-Term Efficacy in Allergic Rhinoconjunctivitis
Efficacy of sublingual specific immunotherapy on allergic asthma and rhinitis in children s real life
European Review for Medical and Pharmacological Sciences Efficacy of sublingual specific immunotherapy on allergic asthma and rhinitis in children s real life G. DE CASTRO, A.M. ZICARI, L. INDINNIMEO,
Associate Professor Rohan Ameratunga Immunologist & Allergist, Auckland
Associate Professor Rohan Ameratunga Immunologist & Allergist, Auckland Update on desensitisation Associate Professor Rohan Ameratunga GLORIA Module 4: Allergen Specific Immunotherapy A New Zealand perspective
Adherence During Early Allergen Immunotherapy and Strategies to Motivate and Support Patients
Adherence During Early Allergen Immunotherapy and Strategies to Motivate and Support Patients Authors: Natalija Novak, 1 Timo Buhl, 2,3 *Oliver Pfaar 4,5 1. Department of Dermatology and Allergy, University
UNDERSTANDING ALLERGY IMMUNOTHERAPY
UNDERSTANDING ALLERGY IMMUNOTHERAPY Provide Allergy Patients Another Option for Relief How many of your patients suffer from allergies? ALLERGIES ARE A BURDENSOME CONDITION FOR MANY PEOPLE IN THE US. In
Immunotherapy. Chris Doyle Consultant Nurse Respiratory & Allergy Alder Hey Childrens NHS FT. October 18 th 2014
Immunotherapy Chris Doyle Consultant Nurse Respiratory & Allergy Alder Hey Childrens NHS FT Chris.doyle@alderhey.nhs.uk October 18 th 2014 What exactly is Immunotherapy? Medical procedure that uses controlled
According to the 2009 National Health Interview Survey, 7.8% of
REVIEW Subcutaneous and sublingual immunotherapy for allergic rhinitis: What is the evidence? Sarah K. Wise, M.D., 1 and Rodney J. Schlosser, M.D. 2 ABSTRACT Background: Increasing interest in sublingual
Peanut Allergy Desensitization
Peanut Allergy Desensitization DERRICK R. WARD, MD KANSAS CITY ALLERGY AND ASTHMA ASSOCIATES KAAP SPRING CME MEETING APRIL 24, 2015 Disclosures Speakers Bureau Teva pharmaceuticals Consultant None Research
Ten-Year Experience with Sublingual Immunotherapy for Juniper Pollenosis ABSTRACT
Ten-Year Experience with Sublingual Immunotherapy for Juniper Pollenosis ABSTRACT RATIONALE: Juniper species are major spring allergens in the southwestern USA. We previously reported a study of sublingual
The evolution of allergen immunotherapy from empirical desensitization to immunological treatment
Eur Ann Allergy Clin Immunol VOL 45, SUPPL. 2, 5-10, 2013 C. Incorvaia 1, I. Dell Albani 2, G. Di Cara 3, P. Piras 4, F. Frati 2 The evolution of allergen immunotherapy from empirical desensitization to
The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey
DOI 10.1186/s13601-015-0083-6 RESEARCH Open Access The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey David Price 1*, Glenis Scadding 2, Dermot Ryan 3,4, Claus Bachert
Novakova et al. Health and Quality of Life Outcomes (2017) 15:189 DOI /s z
Novakova et al. Health and Quality of Life Outcomes (2017) 15:189 DOI 10.1186/s12955-017-0764-z RESEARCH Open Access Quality of life improvement after a threeyear course of sublingual immunotherapy in
RightBreathe to help with inhaler prescribing and technique
www.rightbreathe.com RightBreathe to help with inhaler prescribing and technique Dr Azhar Saleem GP Respiratory Lead, Lambeth CCG GP Specialist NHS London Procurement Partnership Clinical Lead RightBreathe
Mohamed Shamji, PhD. CS. FAAAAI
Short Course treatment of Subcutaneous Peptide Hydrolysate from Lolium Perenne - gp-asit+ TM - suppresses Basophil Responses and induces IgGassociated Blocking Antibodies: A RDPCT Mohamed Shamji, PhD.
A world leader in allergy immunotherapy
A world leader in allergy Milestones in the history of ALK ALK was founded on 9th June 1923 when pharmacist Peter Barfod and physician Kaj Baagøe recorded the first pharmaceutically manufactured allergy
ALLERGEN IMMUNOTHERAPY: A PRACTICE PARAMETER THIRD UPDATE SUBLINGUAL ALLERGEN IMMUNOTHERAPY WITH A LIQUID BIRCH
PDF : A PRACTICE PARAMETER THIRD UPDATE SUBLINGUAL WITH A LIQUID BIRCH 1 / 7 2 / 7 3 / 7 allergen immunotherapy pdf Task force report Allergen immunotherapy: A practice parameter third update Chief Editors:
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced by house dust mite allergens
Trebuchon et al. Clinical and Translational Allergy 214, 4:15 RESEARCH Open Access Characteristics and management of sublingual allergen immunotherapy in children with allergic rhinitis and asthma induced
A world leader in allergy immunotherapy
A world leader in allergy immunotherapy Company presentation Per Plotnikof, VP Corporate Communications and IR 1 I ALK at a glance Commercial leader and foremost innovator within respiratory allergies
Authors should appear in this order for PubMed:
1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 Sublingual Immunotherapy: A focused allergen immunotherapy practice parameter update Authors should appear
Effectiveness of Specific Sublingual Immunotherapy in Korean Patients with Atopic Dermatitis
pissn 1013-9087ㆍeISSN 2005-3894 Ann Dermatol Vol. 29, No. 1, 2017 https://doi.org/10.5021/ad.2017.29.1.1 ORIGINAL ARTICLE Effectiveness of Specific Sublingual Immunotherapy in Korean Patients with Atopic
New Frontiers in Allergen Immunotherapy
New Frontiers in Allergen Immunotherapy Bryan Martin, DO, MMAS, FACP. FACOI, FAAAI, DFACAAI President, The American College of Allergy, Asthma & Immunology Emeritus Professor of Medicine and Pediatrics
In Vitro Evaluation of Allergen Potencies of Commercial House
Original Article Allergy Asthma Immunol Res. 215 March;7(2):124-129. http://dx.doi.org/1.4168/aair.215.7.2.124 pissn 292-7355 eissn 292-7363 In Vitro Evaluation of Allergen Potencies of Commercial House
Face to Face on LAIS Mechanism of action and clinical experiences
Kazan, 14-17 May 2014 Face to Face on LAIS Mechanism of action and clinical experiences Mario di Gioacchino Dept. of Medicine and Ageing Science University of Chieti. Italy Enrico Compalati Allergy & Respiratory
Allergens And Allergen Immunotherapy Fourth Edition Clinical Allergy And Immunology
Allergens And Allergen Immunotherapy Fourth Edition Clinical Allergy And Immunology 1 / 6 2 / 6 3 / 6 Allergens And Allergen Immunotherapy Fourth areas of allergens and immunotherapies: pollens animal/insect
Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax ) in children
ClinicoEconomics and Outcomes Research open access to scientific and medical research Open Access Full Text Article Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax ) in
Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies
Controversial Issues in the Management of Childhood Asthma: Insights from NIH Asthma Network Studies Stanley J. Szefler, MD Helen Wohlberg and Herman Lambert Chair in Pharmacokinetics, Head, Pediatric
Sublingual Immunotherapy as a Technique of Allergen Specific Therapy
Sublingual Immunotherapy as a Technique of Allergen Specific Therapy Policy Number: 2.01.17 Last Review: 7/2017 Origination: 7/2006 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City
When and how should oral immunotherapy for food allergy become daily clinical practice?
When and how should oral immunotherapy for food allergy become daily clinical practice? Nikos Papadopoulos Professor Allergy & Paediatric Allergy University of Manchester, University of Athens Disclosures
NIH Public Access Author Manuscript J Allergy Clin Immunol. Author manuscript; available in PMC 2015 March 01.
NIH Public Access Author Manuscript Published in final edited form as: J Allergy Clin Immunol. 2014 March ; 133(3): 846 852.e6. doi:10.1016/j.jaci.2013.08.047. Development of cockroach immunotherapy by
Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Sublingual Immunotherapy as a Technique Page 1 of 24 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Sublingual Immunotherapy as a Technique of Allergen- Specific
Current and Future Prospects for the Treatment of Food Allergy
Current and Future Prospects for the Treatment of Food Allergy Robert A. Wood, MD Professor of Pediatrics and International Health Director, Pediatric Allergy and Immunology Director, Pediatric Clinical
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Oral Immunotherapy Agents Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Immunotherapy Agents Prime Therapeutics will review Prior Authorization
Multiple daily administrations of low-dose sublingual immunotherapy in allergic rhinoconjunctivitis Vasco Bordignon, MD,* and Samuele E.
Multiple daily administrations of low-dose sublingual immunotherapy in allergic rhinoconjunctivitis Vasco Bordignon, MD,* and Samuele E. Burastero, MD Background: Sublingual immunotherapy (SLIT) is an
Outcomes: Efficacy for any AIT: who, what, when and how?
Outcomes: Efficacy for any AIT: who, what, when and how? How is it measured? Regulatory Authority Requirements: new allergen products must demonstrate efficacy & safety Primary outcome: clinical efficacy
Curing Allergy. Characteristics of products for specific allergy management. Jorgen Nedergaard Larsen, PhD. Senior scientist. dk.alk-abello.
Characteristics of products for specific allergy management Jorgen Nedergaard Larsen, PhD Senior scientist jnl @ dk.alk-abello.com 11 May 2012 Introduction to ALK-Abelló Pharmaceutical company devoted
INHALER DEVICES: THE PAST, THE PRESENT, AND THE FUTURE
INHALER DEVICES: THE PAST, THE PRESENT, AND THE FUTURE This symposium took place on 27 th September 2015, as part of the European Respiratory Society International Congress 2015 in Amsterdam, Netherlands
GLORIA Module 4: Allergen Specific Immunotherapy Its safe use: A New Zealand perspective
Update on desensitisation Associate Professor Rohan Ameratunga GLORIA Module 4: Allergen Specific Immunotherapy Its safe use: A New Zealand perspective Procedure Allergen immunotherapy is the administration
The Future of Allergy Treatment Ultra-Fast Allergy Immunotherapy
The Future of Allergy Treatment Ultra-Fast Allergy Immunotherapy 1 Anergis Focus on Allergy Immunotherapy (AIT) High Medical Need and Patient Demand 500 M allergic patients - fastest growing chronic condition
The leading allergy specialist with a history dating back to 1923
The leading allergy specialist with a history dating back to 1923 7% 4 year CAGR 11% 4 year CAGR 33% of global allergy immunotherapy market 2012 Revenue: DKK 2.35b (EUR 314m) 2012 EBITDA: DKK 306m (EUR
Abstract and Introduction
www.medscape.com From Current Opinion in Allergy and Clinical Immunology Clinical Outcome Measures of Specific Immunotherapy Oliver Pfaar; Clemens Anders; Ludger Klimek Published: 07/20/2009 Abstract and
Allergen immunotherapy: from EBM to doctors and patients need
Allergen immunotherapy: from EBM to doctors and patients need Moscow, Marriott Hotel February 28th, 2019 Dr. Franco Frati Medical Department Milan, Italy From the recognition of the pollen to in vivo tests
Sublingual Immunotherapy as a Technique of Allergen Specific Therapy
Sublingual Immunotherapy as a Technique of Allergen Specific Therapy Policy Number: 2.01.17 Last Review: 7/2014 Origination: 7/2006 Next Review: 7/2015 Policy Blue Cross and Blue Shield of Kansas City
ALK at a glance The leading allergy specialist
ALK at a glance The leading allergy specialist 33% of global allergy immunotherapy market Leading R&D pipeline with proven technology Strategic partnerships to globalise tablet portfolio Modern allergy
TREATING ALLERGIC RHINITIS
TREATING ALLERGIC RHINITIS Prof. Dr. Jean-Baptiste Watelet, MD Department of Otorhinolaryngology Ghent University Hospital Ghent, Belgium Allergic rhinitis (AR) is a nasal disease with the presence of
COMPARISON OF CLINICAL EFFICACY AND SAFETY KUWAITI SCHOOLCHILDREN WITH SEASONAL ALLERGIC RHINITIS
Original article DOI 10.5457/p2005-114.37 COMPARISON OF CLINICAL EFFICACY AND SAFETY SUBCUTANEOUS AND SUBLINGUAL IMMUNOTHERAPY IN KUWAITI SCHOOLCHILDREN WITH SEASONAL ALLERGIC RHINITIS Nermina ARIFHODZIC
Clinical Study Report SLO-AD-1 Final Version DATE: 09 December 2013
1. Clinical Study Report RANDOMIZED, OPEN, PARALLEL GROUP, PHASE IIIB STUDY ON THE EVALUATION OF EFFICACY OF SPECIFIC SUBLINGUAL IMMUNOTHERAPY IN PAEDIATRIC PATIENTS WITH ATOPIC DERMATITIS, WITH OR WITHOUT
Accepted Manuscript. Shared Decision Making for the Allergist
Accepted Manuscript Shared Decision Making for the Allergist Michael S. Blaiss, Gary C. Steven, Bruce Bender, Don A. Bukstein, Eli O. Meltzer, Tonya Winders PII: S1081-1206(18)30710-5 DOI: https://doi.org/10.1016/j.anai.2018.08.019
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Oral Immunotherapy Agents Page 1 of 14 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Oral Immunotherapy Agents (Grastek, Oralair, Ragwitek ) Prime Therapeutics
Margitta Worm 1*, Sabina Rak 2, Frédéric de Blay 3, Hans-Jorgen Malling 4, Michel Melac 5, Véronique Cadic 5 and Robert K Zeldin 5
Worm et al. Clinical and Translational Allergy 214, 4:7 RESEARCH Sustained efficacy and safety of a 3IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis:
Cost-effectiveness of GRAZAX s for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe
Respiratory Medicine (2007) 101, 1885 1894 Cost-effectiveness of GRAZAX s for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe G.W. Canonica a, P.B. Poulsen b,, U. Vestenbæk c
ODACTRA House Dust Mite (Dermatophagoides farina & Dermatophagoides pteronyssinus) allergen extract sublingual tablet
pteronyssinus) allergen extract sublingual tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan.
Metaanalysis of the Efficacy of Sublingual Immunotherapy in the Treatment of Allergic Asthma in Pediatric Patients, 3 to 18 Years of Age
www.medscape.com To Print: Click your browser's PRINT button. NOTE: To view the article with Web enhancements, go to: http://www.medscape.com/viewarticle/576095 Metaanalysis of the Efficacy of Sublingual
Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose
DOI 10.1186/s13601-015-0088-1 Clinical and Translational Allergy REVIEW Open Access Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300 index of reactivity dose Pascal Demoly 1*,
Review on immunotherapy in airway allergen sensitised patients
REVIEW Review on immunotherapy in airway allergen sensitised patients J.P.M van der Valk*, N.W. de Jong, R. Gerth van Wijk Department of Internal Medicine, section of Allergology, Erasmus MC, Rotterdam,
Rhinitis, sinusitis, and upper airway disease
Rhinitis, sinusitis, and upper airway disease Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen induced rhinoconjunctivitis
Scientific Contribution 2017
HAL Allergy Roadmap to Innovative and Registered Allergen Immunotherapy Registered Immunotherapy Phase III Phase II Pivotal Pre Clinical Phase I Dose Tolerability Dose Finding Scientific Contribution 27
The effect of a new communication template on anticipated willingness to initiate or resume allergen immunotherapy: an internet-based patient survey
Calderon et al. Allergy, Asthma & Clinical Immunology (2015) 11:17 DOI 10.1186/s13223-015-0083-z ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY RESEARCH Open Access The effect of a new communication template on
Format. Allergic Rhinitis Optimising Mananagement. Degree of Quality of life Restriction in the Allergic Patient. The allergy epidemic:
Format Allergic Rhinitis Optimising Mananagement Dr Dominic Mallon FRACP FRCPA Clinical Immunologist and Allergist Fiona Stanley Hospital Impact of allergic rhinitis Diagnosis and management of allergic
Sublingual Immunotherapy as a Technique of Allergen Specific Therapy
Sublingual Immunotherapy as a Technique of Allergen Specific Therapy Policy Number: 2.01.17 Last Review: 7/2018 Origination: 7/2006 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City
An accelerated dose escalation with a grass pollen allergoid is safe and well tolerated: a randomized open label phase II trial
DOI 10.1186/s13601-016-0093-z Clinical and Translational Allergy RESEARCH Open Access An accelerated dose escalation with a grass pollen allergoid is safe and well tolerated: a randomized open label phase